In the latest quarter, 15 analysts provided ratings for CVS Health CVS, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 7 | 6 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 3 | 2 | 0 | 0 |
| 2M Ago | 2 | 2 | 2 | 0 | 0 |
| 3M Ago | 0 | 1 | 2 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $68.4, with a high estimate of $85.00 and a low estimate of $58.00. Witnessing a positive shift, the current average has risen by 4.16% from the previous average price target of $65.67.
Investigating Analyst Ratings: An Elaborate Study
The standing of CVS Health among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Ben Hendrix | RBC Capital | Lowers | Outperform | $58.00 | $68.00 |
| Kevin Caliendo | UBS | Raises | Neutral | $62.00 | $60.00 |
| Andrew Mok | Barclays | Lowers | Overweight | $71.00 | $75.00 |
| Stephen Baxter | Wells Fargo | Lowers | Equal-Weight | $60.00 | $61.00 |
| Ann Hynes | Mizuho | Lowers | Outperform | $66.00 | $73.00 |
| Andrew Mok | Barclays | Lowers | Overweight | $75.00 | $82.00 |
| David Macdonald | Truist Securities | Raises | Buy | $76.00 | $66.00 |
| Andrew Mok | Barclays | Raises | Overweight | $82.00 | $63.00 |
| Elizabeth Anderson | Evercore ISI Group | Raises | Outperform | $75.00 | $62.00 |
| Charles Ryhee | TD Cowen | Raises | Buy | $85.00 | $59.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Neutral | $62.00 | $62.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Neutral | $62.00 | $62.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Neutral | $62.00 | $62.00 |
| Ben Hendrix | RBC Capital | Maintains | Outperform | $68.00 | $68.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Neutral | $62.00 | $62.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CVS Health. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CVS Health compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for CVS Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of CVS Health's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on CVS Health analyst ratings.
Get to Know CVS Health Better
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
CVS Health: Delving into Financials
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining CVS Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.31% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: CVS Health's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 0.09%, the company may face hurdles in effective cost management.
Return on Equity (ROE): CVS Health's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 0.12%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.03%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.1.
How Are Analyst Ratings Determined?
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
